Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
| Autor: | Jelena Berendika, Gordan Nikic, Gordana Malčić Kecman, Božana Babić, Ivanka Rakita, Sasa Jungic, Biljana Tubić, Milka Vjestica, Zdenka Gojkovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Chemotherapy business.industry Standard treatment medicine.medical_treatment Perineural invasion Urology Neoplasms. Tumors. Oncology. Including cancer and carcinogens Salivary duct carcinoma Case Report Parotidectomy Trastuzumab medicine.disease Adjuvant therapy Carboplatin Parotid gland chemistry.chemical_compound medicine.anatomical_structure Oncology chemistry medicine business RC254-282 |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 14, Iss 1, Pp 610-615 (2021) |
| ISSN: | 1662-6575 |
| Popis: | Malignant salivary gland tumors form 11% of all head and neck tumors. Salivary duct carcinoma (SDC) of the parotid gland is an uncommon and highly aggressive tumor accounting for 2% of all salivary gland malignancies. The fourth edition of the WHO Classification of Head and Neck Tumors reported global annual incidence of 0.4–2.6/100,000 people. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. Here, we present a case of an SDC of the parotid gland in a 55-year-old female. She presented with a painless swelling behind her right ear. Surgery was performed, and total right parotidectomy was done along with selective neck dissection (levels II, III, VA). The pathology report concluded that it was a G3 (poorly differentiated) SDC (micropapillary variant) with lymphovascular and perineural invasion. The clinical stage of the disease was T4aN2bM0. Adjuvant therapy consisted of concurrent radiation (TD 66 Gy) and chemotherapy with weekly paclitaxel (45 mg/m2), carboplatin (AUC 1.5), and trastuzumab (2 mg/kg; THC) for 6 weeks followed by 4 cycles of THC every 3 weeks. Adjuvant trastuzumab was continued for a total of 1 year. She is still without the evidence of the disease 7 years later. The consensus regarding the use of adjuvant chemotherapy does not exist. Based on all the data that have been presented before, the conclusion is that we need new treatment modalities to improve the outome of this aggressive disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|